Patients with inoperable, advanced HER2-positive bile duct cancer
Study objective:
Efficacy and safety of zanidatamab in combination with standard therapy compared to standard therapy
Contact person:
Professor Dr. Michael Quante
CARP
Target group:
Patients with cholangiocarcinoma (bile duct cancer)
Study objective:
Treatment of cholangiocarcinoma with radiofrequency ablation or photodynamic therapy and investigation of side effects and quality of life
Contact person:
Dr. Armin Küllmer
DESTINY-Biliary Tract Cancer-01 D781PC00001
Target group:
Untreated patients with locally advanced or metastatic HER2-positive bile duct cancer
Study objective:
To evaluate the efficacy of trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate, in combination with the antibody rilvegostomig as first-line therapy. The aim is to determine the overall survival time compared to standard therapy.
Contact person:
Prof. Dr. Michael Quante
FIRE-8
Target group:
Patients with histologically confirmed adenocarcinoma of the colon or rectum
Study objective:
Comparison of the efficacy of treatment with trifluridine/tipiracil plus panitumumab with that of trifluridine/tipiracil plus bevacizumab (nucleoside analogs in comparison with various approved antibodies)
Contact person:
Professor Dr. Michael Quante
FIRE-9
Target group:
Patients with colorectal carcinoma and resected primary tumor
